NewEdge Advisors’s Gain Therapeutics GANX Stock Holding History

NewEdge Advisors’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.5K	Hold	10,600	–	–	﹤0.01%	3337
2026 Q1	$20.6K	Hold	10,600	–	–	﹤0.01%	3189
2025 Q4	$34.1K	Hold	10,600	–	–	﹤0.01%	3079
2025 Q3	$18.8K	Hold	10,600	–	–	﹤0.01%	3145
2025 Q2	$19.1K	Hold	10,600	–	–	﹤0.01%	2976
2025 Q1	$20.2K	Buy	+10,600	New	+$23.5K	﹤0.01%	2860
2024 Q2	–	Sell	-225	Closed	-$848	–	3877
2024 Q1	$848	Buy	+225	New	+$933	﹤0.01%	3529
2023 Q4	–	Sell	-11,050	Closed	-$36.2K	–	3795
2023 Q3	$36.2K	Hold	11,050	–	–	﹤0.01%	2193
2023 Q2	$49.5K	Buy	11,050 +550	+5%	+$2.69K	﹤0.01%	2089
2023 Q1	$54.1K	Buy	+10,500	New	+$42.9K	﹤0.01%	1967

Other funds holding GANX

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PCM

Potomac Capital Management New York $147M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

NewEdge Advisors's GANX Position: Q2 2026 in Review

NewEdge Advisors held its Gain Therapeutics (GANX) position steady in Q2 2026 at 10,600 shares worth $21.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3337.

NewEdge Advisors first reported a position in GANX in Q1 2023 and has held it in 10 quarters since. The position peaked at $54.1K in Q1 2023. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

NewEdge Advisors held 10,600 shares of Gain Therapeutics worth $21.5K as of Q2 2026.
NewEdge Advisors left its Gain Therapeutics share count unchanged in Q2 2026.
Gain Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3337 holding.
NewEdge Advisors first reported a position in Gain Therapeutics in Q1 2023 and has held it in 10 quarters since.
NewEdge Advisors's Gain Therapeutics position peaked at $54.1K in Q1 2023.
50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.